Melbourne-based biotech firm PolyActiva, which has spent 15 years developing an eye-implant technology to treat glaucoma, has won a $27 million investment from the National Reconstruction Fund Corporation as part of a $40 million Series C round.
The NRFC’s $27 million commitment was a part of PolyActiva’s $40 million Series C round, with the investment being used to expand and consolidate its operations into a single facility that encompasses R&D, analytics and manufacturing and to grow its technical workforce.
The company, which currently employs 25 staff as well as four full-time research contractors through Monash University, is expected to immediately add six new primarily technical staff to its roster.
Want to know how this story ends?
Become a subscriber for complete access to all stories on InnovationAus.com and our daily newsletter.
Do you know more? Contact James Riley via Email.